CORTINOVIS DIEGO LUIGI

Peters, S., Schulz, C., Reck, M., Prabhash, K., Kowalski, D., Szczesna, A., et al. (2025). Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study. JOURNAL OF THORACIC ONCOLOGY, 20(12), 1843-1850 [10.1016/j.jtho.2025.07.115]. Dettaglio

Filippi, A., García Campelo, M., Paoli, J., Kowalski, D., Bennati, C., Borghetti, P., et al. (2025). Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study. ESMO OPEN, 10(9) [10.1016/j.esmoop.2025.105560]. Dettaglio

Reale, M., Scattolin, D., Vitale, A., Passiglia, F., Grisanti, S., Macerelli, M., et al. (2025). Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database. LUNG CANCER, 209(November 2025) [10.1016/j.lungcan.2025.108762]. Dettaglio

Leighl, N., Paz-Ares, L., Abreu, D., Hui, R., Baka, S., Bigot, F., et al. (2025). LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy. JOURNAL OF THORACIC ONCOLOGY, 20(10), 1489-1504 [10.1016/j.jtho.2025.05.020]. Dettaglio

Garassino, M., Khalifa, J., Reck, M., Chouaid, C., Bischoff, H., Reinmuth, N., et al. (2025). Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trial. ESMO OPEN, 10(6) [10.1016/j.esmoop.2025.105071]. Dettaglio